Jean-Luc Vanderheyden Email and Phone Number
Jean-Luc Vanderheyden work email
- Valid
- Valid
Jean-Luc Vanderheyden personal email
Jean-Luc Vanderheyden phone numbers
Corporate research and product development executive with over twenty five years experience in senior management positions at biotechnology and large healthcare companies.Developing molecular imaging and theranostics agents from discovery and development through early stage clinical trials and commercialization. Expert in scientific, commercial and research analyses related to advanced technologies involving all forms of imaging, isotope supply worldwide and radiation therapy. Serve on NCI SBIR, Innovative Medicines Initiative (IMI), Swedish Foundation for Strategic Research and Society review panels. Focus on clinical development for oncology, cardiology, neurology, cell signaling and inflammation. Member of Quantitative Imaging Biomarker Alliance (QIBA) of RSNA on PET Amyloid Biomarker. Successfully completed all requirements for the I-Corps @ NIH Program.Specialties: Drug Development, Pharmacy, Radiopharmacy, Chemistry, Radiochemistry, Biomarkers, GMP, Pharmacology, Molecular Imaging, Theranostics, SPECT and PET imaging equipments, Operation Management, Radiation Safety.Co-led a joined European-US team for the OctreoScan NDA until FDA approval, with emphasis on technology transfer and total quality management. Led the “radiolabeled peptides” unit with key industrial and academics partners, and GE's molecular imaging strategy as it relates to integrated offerings to and partnerships with academic institutions. Visiting Associate Professor at the University of Massachusetts Nuclear Medicine/Radiology Division, working closely with the faculty on characterization of preclinical probes. • Dual citizenship: USA and Belgium
Oncidium Foundation
View- Website:
- oncidium-life.org
- Employees:
- 54
-
Head Of Oncidium Foundation UsaOncidium FoundationDousman, Wi, Us
-
Owner / Executive ConsultantJlvmi Consulting Llc Feb 2012 - Present• Provide consulting in the areas of pharmacy, radiochemistry and radiopharmacy of imaging agents, including Chemistry, Manufacturing and Controls, Pharmacology/Toxicology sections of IND’s, ANDA’s and DMF’s, covering C-13 metabolic MRI, fluorescent, PET and SPECT agents (small molecules, antibodies and fragments, peptides, recombinant DNA proteins). Additional areas of expertise cover safety and radiation safety, research and laboratory management. • Successfully completed all requirements for the I-Corps @ NIH Program (June-August 2016).• Reviewer to the NCI SBIR for Novel Imaging Agents, the Innovative Medicines Initiative (IMI), the Swedish foundation for Strategic Research, the Society of Nuclear Medicine for Oncology – Basic Science track and serving as a peered journal's reviewer on topics of molecular imaging, radiopharmaceuticals and apoptosis/angiogenesis imaging. -
Global Mi Scientist And Research ManagerGe Healthcare Nov 2005 - Dec 2011Chicago, Us• Led the global molecular imaging scientific strategy, especially as it relates to integrated offerings to and partnerships with academic institutions.• Mobilized Molecular Imaging cross-business effort across divisions and drove the foundation of Molecular Imaging/Molecular Medicine marketing plan with SWAT and trends.• Delivered a Marketing Communication strategy and deliverables in training materials internally and with target audience, thus positioning GEHC as Molecular Imaging Leader.• Simplified and lead the processes of managing Academic collaborators affecting both business numbers and NPS (net promoter score) with a 15 point growth.• Delivered on key external interface for the Enterprise and Academic Segments, affecting over $200M of deals to advance the company’s position in the Molecular Imaging domain. Recently served as the direct interaction for Academic manufacturers facing the December 12, 2011 deadline on PET radiopharmaceuticals. • Effectively positioned $18M Radiopharmaceutical Technologies solutions by bridging the commercial/research gap, consulting on the current and future trends in molecular medicine, biomarker and ligand development, as well as their relationship to diagnostic and therapeutic applications. -
Visiting Associate Professor, Nuclear Medicine/RadiologyUniversity Of Massachusetts 2002 - 2005Boston, Massachusetts, Us• Collaborated with Prof. Hnatowich on the development of radiolabeled antisense oligonucleotides and TAT peptides for diagnostic and therapy. • Co-investigator on four proposed grants for the use of radiolabeled annexin in conjunction with small animal imagers and methods for improving product clearance.• Participated in a study of farnesyl transferase therapy using an EGF receptor probe. -
Vp Of R&DTheseus Imaging/North American Scientific Inc. 2001 - 2005• Led a team in the execution of product and assay development, formulation, pharmacology, toxicology and quality control of an apoptosis imaging agent that reached Phase II clinical studies.• Managed CRO’s for the manufacturing and testing of organic intermediate, protein biopharmaceutical and a lyophilized component.• Developed the data and wrote the CMC and Pharmacology/Toxicology sections of the company’s IND and European regulatory applications.• Collaborated with QA to develop the company’s SOP program.• Safety Officer, responsible for radiation, biological and chemical safety of the laboratory.• Led research activities, extending molecular imaging of apoptosis to PET, MRI and optical imaging; Managed preclinical activities with over 25 research collaborations (governmental, university and industrial) worldwide.• Active member of the intellectual property team.• Wrote, develop and submitted as Principal Investigator a funded fast track SBIR grant ($850,000)
-
Director, Us Nuclear Medicine R&DCovidien (Formerly Mallinckrodt Medical/Tyco Healthcare), Now Curium 1991 - 2001• Developed strategic R&D plans, managed the R&D budget and coordinated research activities worldwide.• Responsible for a Technology Review process that analyzed BD opportunities.• Responsible for the coordination of all phases of an R&D reengineering (impacting 120 employees), active member of project teams covering communications, project management, globalization, human resources, SOP, training, information technology for the Medical/Regulatory group. • Participated in a TQM team addressing transfer of technology from R&D to plant. • Co-led a joined European-US team for the filing of OctreoScan NDA until FDA approval in June 94, with emphasis on resolving issues on manufacturing pre-approval inspection.• Initiated and led a “radiolabeled peptides” group interacting with Sandoz/Novartis, Monsanto/Searle and academics, and resulting in the successful production of in-house peptide for early patient studies.
-
Section Head, Analytical Laboratory ServicesNeorx 1985 - 1991Us• Assured that all radiolabeled products delivered to the clinics met cGMP standards, and supervised laboratory data from clinical trials (pharmacokinetics, immunology). • Submitted and supported multiple patent applications covering therapeutic isotope applications.• Coordinated the Rhenium antibody project, including chemistry section of IND (colon cancer) to the clinical stage, expanded the preclinical studies to lung and ovarian cancer IND’s. Promoted to company-wide Rhenium project manager.• Contributed data for the chemistry and toxicology sections of the company’s IND (Tc-99m antibody for diagnosis of melanoma). • Set up an R&D laboratory to handle diagnostic and therapeutic radioisotopes. • Co-investigator on a Phase 1 and a Phase 2 SBIR grants totaling $550,000.
Jean-Luc Vanderheyden Skills
Jean-Luc Vanderheyden Education Details
-
I-CorpsBusiness/Start-Ups -
University Of CincinnatiAnalytical Chemistry
-
Université Libre De BruxellesPharmacy
Frequently Asked Questions about Jean-Luc Vanderheyden
What company does Jean-Luc Vanderheyden work for?
Jean-Luc Vanderheyden works for Oncidium Foundation
What is Jean-Luc Vanderheyden's role at the current company?
Jean-Luc Vanderheyden's current role is Head of Oncidium Foundation USA.
What is Jean-Luc Vanderheyden's email address?
Jean-Luc Vanderheyden's email address is jl****@****ink.net
What is Jean-Luc Vanderheyden's direct phone number?
Jean-Luc Vanderheyden's direct phone number is +177442*****
What schools did Jean-Luc Vanderheyden attend?
Jean-Luc Vanderheyden attended I-Corps, University Of Cincinnati, Université Libre De Bruxelles.
What skills is Jean-Luc Vanderheyden known for?
Jean-Luc Vanderheyden has skills like Drug Development, Clinical Trials, R&d, Molecular Imaging, Technology Transfer, Chemistry, Fda, Gmp, Biomarkers, Cancer, Pharmacology, Protein Chemistry.
Who are Jean-Luc Vanderheyden's colleagues?
Jean-Luc Vanderheyden's colleagues are Tala Allahham, Jean Karlo Rojas Sernaqué, Atekka Chabanse, Dorian Buekenhoudt, Ivan E. Diaz-Meneses, Maria Jose Bastianello, Luisa Fabiola Portugal Escalante.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial